GW succumbs to a Jazz overture
A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
Marinus finds a path forward in rare epilepsies
Marinus celebrates pivotal trial success with ganaxolone, but a quick approval could depend on lenient regulators.
Ovid joins the rare epilepsy race
Ovid Therapeutics gets a mid-stage win in Dravet syndrome, but might have a hard time going up against Zogenix’s Fintepla.
Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Rett failure sets up thin pipeline
Newron’s failure in Rett syndrome leaves the late-stage pipeline to GW Pharma, Acadia and Anavex.
Zogenix hands GW a win
A phase III Lennox-Gastaut trial sees Fintepla meet statistical significance but fail the test of clinical relevance.
Upcoming events – Genmab's route to market, and late-stage data for Zogenix
Genmab is seeking data to position tisotumab as its first in-house launch, while Zogenix wants Fintepla to challenge GW in Lennox-Gastaut syndrome.
